Latest News for: cml

Edit

Preliminary results for the year ended 31 March 2026 (CML Microsystems plc)

Public Technologies 17 Jun 2026
CML Microsystems plc published this content on June 17, 2026, and is solely ...
Edit

Macon Valley Capital, LLC v. Fisher et al - Memorandum Decision (cml) (United States Bankruptcy Court for the District of Oregon)

Public Technologies 16 Jun 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer ... (noodl.
Edit

World premiere at Eurosatory 2026: Rheinmetall presents the CML multi launcher for the FV-014 Loitering Munition (Rheinmetall AG)

Public Technologies 16 Jun 2026
Rheinmetall presents the CML multi launcher for the FV-014 Loitering Munition ... At Eurosatory 2026, Rheinmetall has unveiled for the first time a multi launcher for its LMS FV-014, the Containerized Missile Launcher (CML).
Edit

EHA 2026 | HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR::ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML) (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 12 Jun 2026
At EHA 2026, data were presented from two clinical studies evaluating HS-10382 administered as monotherapy and in combination with Flumatinib in patients with newly diagnosed chronic-phase CML (CML-CP) ... About CML.
Edit

CML Applauds Governor Polis’ Veto of Senate Bill 26-184

Pagosa Daily Post 08 Jun 2026
“We are grateful that Governor Polis recognized the serious fiscal and procedural concerns that SB26-184 posed for Colorado’s municipalities,” said Kevin Bommer, CML Executive Director.
Edit

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

The Daily Record - Dunn 01 Jun 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ. AAPG; ....
Edit

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

The Daily Record - Dunn 01 Jun 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ. AAPG; ....
Edit

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 (Ascentage Pharma Group International)

Public Technologies 01 Jun 2026
... with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs.
Edit

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 (Ascentage Pharma Group International)

Public Technologies 01 Jun 2026
... with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs.
Edit

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

PR Newswire 12 May 2026
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR..ABL1 gene fusion, the oncogenic driver for patients living with CML.
Edit

Cabinet approves two more semiconductor manufacturing units with cumulative investment of more than Rs. 3,900 crore

Projects Monitor 06 May 2026
The Union Cabinet chaired by the Prime Minister Shri Narendra Modi approved two ...
Edit

Prospectus by Investment Company (Form 497) (Cml Variable Annuity Account A)

Public Technologies 27 Apr 2026
). Supplement dated April 27, 2026 ... Account A. Account B. Issued by Massachusetts Mutual Life Insurance Company ... Cml Variable Annuity Account A published this content on April 27, 2026, and is solely responsible for the information contained herein.
Edit

Prospectus by Investment Company (Form 497) (Cml Variable Annuity Account B)

Public Technologies 27 Apr 2026
). Supplement dated April 27, 2026 ... Account A. Account B. Issued by Massachusetts Mutual Life Insurance Company ... Cml Variable Annuity Account B published this content on April 27, 2026, and is solely responsible for the information contained herein.
Edit

NCCN Announces Awards for Improvement Initiatives for Chronic Myeloid Leukemia (CML)

PR Newswire 23 Apr 2026
The National Comprehensive Cancer Network announces funding for selected quality improvement research projects to utilize digital tools for improving decision-making and quality of life for people with CML.
Edit

Annual Notice of Securities Sold (Form 24F-2NT) (Cml Variable Annuity Account B)

Public Technologies 27 Mar 2026
Cml Variable Annuity Account B published this content on March 27, 2026, and is ...

Article Search

tools
×
×
×
×